News

The grant allows both the companies to jointly develop a preclinical program on a potential new treatment for stroke patients. The program is aimed to deliver NeuroVive’s cyclosporin

The decision was made because Astellas found it was difficult to find a partner for the Phase III clinical development and commercialization of darexaban. The company also considered

The NoA includes claims directed to the use of Zertane with a class of drugs called phosphodiesterase type 5 (PDE5) inhibitors commonly used for the treatment of ED

The first grant entitled ‘In Vitro Tools for Preclinical Analysis of Cognitive Therapies for Schizophrenia’ for the development of preclinical assays that accurately model human cognitive processes. Galenea

Additionally, Onyx has requested priority review of the application, which reduces the time the FDA takes to review a new drug application. Onyx Research and Development and Technical

Colesevelam, an orally administered, bile-acid sequestrant showed efficacy in reducing LDL-C lipoproteins and drug-interaction and tolerability profile comparable to placebo. Valeant chairman and CEO Michael Pearson said clinical

The MycoDiverse library is a collection of 10,000 refined fractions from fermentations of higher fungi, developed using the company’s technology to stimulate secondary metabolite production. The collection is

The trial aims to investigate the safety and tolerability of YM’s JAK1/JAK2 inhibitor, as well as its efficacy in reducing spleen size, improving constitutional symptoms and reducing transfusion

The company said there are no therapies for patients with LAL Deficiency. However, SBC-102 can possibly be a disease modifying long-term enzyme replacement therapy for patients including infants,